Abstract
Allogeneic BMT for severe aplastic anemia is associated with a significant rate of graft rejection, especially in patients who have been previously transfused. We report a child with aplastic anemia who rejected donor marrow twice despite adequate immunosuppression as part of the conditioning therapy but engrafted successfully following combined administration of three modalities of immunosuppression: antithymocyte globulin, total lymphoid irradiation and the monoclonal antibody Campath-1G. Restriction fragment length polymorphism studies > 1 year after BMT show full donor hematopoiesis with no evidence of autologous recovery.
MeSH terms
-
Alemtuzumab
-
Anemia, Aplastic / chemically induced
-
Anemia, Aplastic / surgery*
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neoplasm
-
Antigens, CD
-
Antigens, Neoplasm*
-
Antilymphocyte Serum / therapeutic use
-
Bone Marrow Transplantation / adverse effects
-
Bone Marrow Transplantation / immunology
-
Bone Marrow Transplantation / methods*
-
CD52 Antigen
-
Child, Preschool
-
Glycoproteins*
-
Graft Rejection
-
Humans
-
Immunosuppression Therapy / methods*
-
Lymphoid Tissue / radiation effects
-
Male
-
Reoperation
-
Tetracycline / adverse effects
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neoplasm
-
Antigens, CD
-
Antigens, Neoplasm
-
Antilymphocyte Serum
-
CD52 Antigen
-
CD52 protein, human
-
Glycoproteins
-
Alemtuzumab
-
Tetracycline